Biotronik Addresses US CRM Market With Its Rivacor And Acticor Lines
The company recently launched six new implantable high-voltage cardiac rhythm management devices with the thin elliptical BIOshape to minimize the risk of skin erosion around the device pocket. Rivacor and Acticor also feature Biotronik's DX leadless atrial diagnostic technology, and MRI AutoDetect which automatically switches the device to a MR-safe mode when it enters a magnetic resonance imaging environment.
You may also be interested in...
Interview: New Biotronik CMO David Hayes Builds Physician Education, Clinical Trial Relationships
In an interview with Medtech Insight, Biotronik president Ryan Walters explained why the former Mayo Clinic cardiologist was the right choice to be the first CMO in the company's history and David Hayes discussed his reasons for taking the job.
Biotronik Rolls Out Biomonitor III Injectable Cardiac Monitor
The company says Biomonitor III documents suspected arrhythmias or unexplained syncope in patients who have experienced cardiac arrhythmias or who are at risk for cardiac arrhythmias.
SENSE Results Support Biotronik’s DX System For Atrial Sensing Without An Atrial Lead
Results of the SENSE trial showed Biotronik’s DX system, which is available in both ICD and CRT-D devices, can detect atrial high-rate episodes as effectively as dual-chamber ICDs and better than single-chamber ICDs even though it does not have an atrial sensing lead.